Differential effects of CD40 stimulation on normal and neoplastic cell growth

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 4, 2000, Pages 225-233

  Ziebold, Jamie L ^a   Hixon, Julie ^b   Boyd, Ann ^c   Murphy, William J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c HOOD COLLEGE   (United States)

Author keywords

Apoptosis; CD40; Interferon ; Lymphoma; Transformed

Indexed keywords

CD40 ANTIGEN;

ADENOCARCINOMA; B CELL LYMPHOMA; BREAST TUMOR; CARCINOMA; CELL DEATH; COMPARATIVE STUDY; FEMALE; HUMAN; METABOLISM; PAGET NIPPLE DISEASE; REVIEW;

ADENOCARCINOMA; ANTIGENS, CD40; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; CELL DEATH; FEMALE; HUMANS; LYMPHOMA, B-CELL;

EID: 0034575636     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. ALLEN R. C., ARMITAGE R. J., CONLEY M. E., ROSENBLATT H., JENKINS N. A., COPELAND N. G., BEDELL M. A., EDELHOFF S., DISTECHE C. M. and SIMONEAUX D. K. (1993): CD40 ligand gene defects responsible for X-Iinked hyper-IgM syndrome. Science, 259, 990-993.
2. ARMITAGE R. J., FANSLOW W. C., STROCKBINE L., SATO T. A., CLIFFORD K. N., MACDUFF B. M., ANDERSON D. M., GIMPEL S. D., DAVIS-SMITH T., MALISZEWSKI C. R., CLARK E. A., SMITH C. A., GRABSTEIN K. H., COSMAN D. and SPRIGGS M. K. (1992): Molecular and biological characterization of a murine ligand for CD40. Nature, 357, 80-82.
3. ARMITAGE R. J., TOUGH T. W., MACDUFF B. M., FANSLOW W. C., SPRIGGS M. K., RAMSDELL F. and ALDERSON M. R. (1993): CD40 ligand is a T cell growth factor. Eur. J. Immunol., 23, 2326-2331.
4. ARPIN C., DECHANET J., KOOTEN C. V., MERVILLE P., GROUARD G., BRIERE F., BANCHEREAU J. and LIU Y. (1995): Generation of memory B cells and plasma cells in vitro. Science, 268, 720-722.
5. BAKER M. P., ELIOPOULOS A. G., YOUNG L. S., ARMITAGE R. J., GREGORY C. D. and GORDON J. (1998): Prolonged phenotypic, functional, and molecular change in group I Burkitt's lymphoma on short-term exposure to CD40 ligand. Blood, 92, 2830-2843.
6. BANCHEREAU J., BAZAN F., BLANCHARD D., BRIERE F., GALIZZI J. P., KOOTEN C., LIU Y. J., ROUSSET F. and SAELAND S. (1994): The CD40 antigen and its ligand. Annu. Rev. Immunol., 12, 881-922.
7. BANCHEREAU J., PAOLI P. D., VALLE A., GARCIA E. and ROUSSET F. (1991): Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science, 251, 70-72.
8. CARBONE E., RUGGIERO G., TERRAZZANO G., PALOMBA C., MANZO C., FONTANA S., SPITS H., KARRE K. and ZAPPACOSTA S. (1997): A new mechanism of NK cytotoxicity activation. The CD40-CD40 ligand interaction. J. Exp. Med., 185, 2053-2060.
9. CLARK E. A. and LEDBETTER J. A. (1986): Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. USA, 83, 4494-4498.
10. FLUCKIGER A. C., ROSSI J. F., BUSSEL A., BRYON P., BANCHEREAU J. and DEFRANCE T. (1992): Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood, 80, 3173-3181.
11. FUNAKOSHI S., BECKWITH M., FANSLOW W., LONGO D. L. and MURPHY W. J. (1995): Epstein-Barr virus induced human B-cell lymphoma arising in HuPBL-SCID chimeric mice. Characterization and the role of CD40 stimulation in their treatment and prevention. Pathobiology, 63, 133-142.
12. FUNAKOSHI S., LONGO D. L., BECKWITH M., CONLEY D. K., TSARFATY G., TSARFATY I., ARMITAGE R. J., FANSLOW W. C., SPRIGGS M. K. and MURPHY W. J. (1994): Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood, 83, 2787-2794.
13. FUNAKOSHI S., LONGO D. L. and MURPHY W. J. (1996): Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J. Immunother., 19, 93-101.
14. FUNAKOSHI S., TAUB D. D., ANVER M. R., RAZIUDDIN A., ASAI O., REDDY V., RAGER H., FANSLOW W. C., LONGO D. L. and MURPHY W. J. (1997): Immunologic and hematopoietic efects of CD40 simulation after syngeneic bone marrow transplantation in mice. J. Clin. Invest., 99, 484-491.
15. FUNAKOSHI S., TAUB D. D., ASAI O., HIRANO A., RUSCETTI F. W., LONGO D. L. and MURPHY W. J. (1997): Effects of CD40 stimulation in the prevention of human EB V-lymphomagenesis. Leuk. Lymphoma, 24, 187-199.
16. GAUCHAT J., HENCHOZ S., FATTAH D., MAZZEI G., AUBRY J., JOMOTTE T., DASH L., PAGE K., SOLARI R., ALDEBERY D., CAPRON M., DAHINDEN C. and BONNEFOY J. (1995): CD40 ligand is functionally expressed on human eosinophils. Eur. J. Immunol., 25, 863-865.
17. GHETIE M., PICKER L. J., RICHARDSON J. A., TUCKER K., UHR J. W. and VITETTA E. S. (1994): Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing growth arrest. Blood, 83, 1329-1336.
18. GRAF D., KORTHAUER U., MAGES H. W., SENGER G. and KROCZEK R. A. (1992): Cloning of TRAP, a ligand for CD40 on human T cells. Eur. J. Immunol., 22, 3191-3194.
19. GRAMMAR A. C., BERGMAN M. C., MIURA Y., FUJITA K., DAVIS L. S. and LIPSKY P. E. (1995): The CD40 ligand expressed by human B cells costimulates B cell responses. J. Immunol., 154, 4996-5010.
20. GRELL M., ZIMMERMAN G., GOTTFRIED E., CHEN C.-M., GRUNWALD U., HUANG D. C. S., LEE Y. -H. W., DURKOP H., ENGELMANN H., SCHEURICH P., WAJANT H. and STRASSER A. (1999): Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J., 18, 3034-3043.
21. GRUSS H., BOIANI N., WILLIAMS D. E., ARMITAGE R. J., SMITH C. A. and GOODWIN R. G. (1994): Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood, 83, 2045-2056.
22. HENN V., SLUPSKY J. R., GRAFE M., ANAGNOSTOPOULOS I., FORSTER R., MULLER-BERGHAUS G. and KROCZEK R. A. (1998): CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 391, 591-594.
23. HESS S. and ENGELMANN H. (1996): A novel function of CD40. Induction of cell death in transformed cells. J. Exp. Med., 183, 159-167.
24. HIRANO A., LONGO D. L., TAUB D. D., FERRIS D. K., YOUNG L. S., ELIOPOULOS A. G., AGATHANGGELOU A., CULLEN N., MACARTNEY J., FANSLOW W. C. and MURPHY W. J. (1999): Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood, 93, 2999-3007.
25. HOLLENBAUGH D., GROSMAIRE L. S., KULLAS C. D., CHALUPNY N. J., BRAESCH-ANDERSEN S., NOELLE R. J., STAMENKOVIC I., LEDBETTER J. A. and ARUFFO A. (1992): The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J., 11, 4313-4321.
26. HU M. H., O'ROURKE K., BOGUSKI M. S. and DIXIT V. M. (1994): A novel ring finger protein interacts with the cytoplasmic domain of CD40. J. Biol. Chem., 269, 30069-30072.
27. ITOH N. and NAGATA S. (1993): A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J. Biol. Chem., 268, 10932-10937
28. JAKOBSON E., JONSSON G., BJORCK P. and PAULIE S. (1998): Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int. J. Cancer, 77, 849-853.
29. JOHNSON P. W. M., WATT S. M., BETTS D. R., DAVIES D., JORDAN S., NORTON A. J. and LISTER T. A. (1993): Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood, 82, 1848-1857.
30. KARMANN K., HUGHES C. C. W., SCHECHNER J., FANSLOW W. C. and POBER J. S. (1995): CD40 on human endothelial cells. Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA, 92, 4342-4346.
31. KISCHKEL F. C., HELLBARDT S., BEHRMANN I., GERMER M., PAWLITA M., KRAMMER P. H. and PETER M. E. (1995): Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J., 14, 5579-5588.
32. KLUIN-NELEMANS H. C., BEVERSTOCK G. C., MOLLEVANGER P., WESSELS H. W., HOOGENDOORN E., WILLEMZE R. and FALKENBURG J. H. F. (1994): Proliferation and cytogenic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. Blood, 84, 3134-3141.
33. KOOTEN C. v. and BANCHEREAU J. (1997): Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol., 9, 330-337.
34. LEOPRECHTING A. v., BRUGGEN P. v. d., PAHL H. L., ARUFFO A. and SIMON J. C. (1999): Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res., 59, 1287-1294.
35. MAZZEI G. J., EDGERTON M. D., LOSBERGER C., LECOANET - HENCHOZ S., GRABER P., DURANDY A., GAUCHAT J. -F., BERNARD A., ALLET B. and BONNEFOY J. -Y. (1995): Recombinant soluble trimeric CD40 ligand is biologically active. J. Biol. Chem., 270, 7025-7028.
36. MURPHY W. J., FUNAKOSHI S., FANSLOW W. C., RAGER H. C., TAUB D. D. and LONGO D. L. (1999): CD40 stimulation promotes human secondary immunoglobulin responses in HuPBL - SCID chimeras. Clin. Immunol., 90, 22-27.
37. NAKAMINE H., MASHI A. S., OKANO M., TAGUCHI Y., PIRRUCCELLO S. J., DAVIS J. R., MAHLOCH M. L., BEISEL K. W., KLEVELAND K., SANGER W. G. and PURTILLO D. T. (1993): Characterization of clonality of Epstein-Barr virus-induced human B lymphoproliferative disease in mice with severe combined immunodeficiency. Am. J. Pathol., 142, 139-147.
38. NONOYAMA S., HOLLENBAUGH D., ARUFFO A., LEDBETTER J. A. and OCHS H. D. (1993): B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J. Exp. Med., 178, 1097-1102.
39. PELLAT-DECEUNYNCK C., AMIOT M., ROBILLARD N., WIJDENES J. and BATAILLE R. (1996): CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest by CD40 stimulation. Cancer Res., 56, 1909-1916.
40. PINCHUK L. M., KLAUS S. J., MAGALETTI D. M., PINCHUK G. V., NORSEN J. P. and CLARK E. A. (1996): Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. J. Immunol., 157, 4363-4670.
41. ROBBINS P. F. and KAWAKAMI Y. (1996): Human tumor antigens recognized by T cells. Curr. Opin. Immunol., 8, 628-636.
42. ROTHE M., SARMA V., DIXIT V. M. and GOEDDEL D. V. (1995): TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science, 269, 1424-1427.
43. SATO T., IRIE S. and REED J. C. (1995): A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS, 358, 113-118.
44. SMITH C. A., FARRAH T. and GOODWIN R. G. (1994): The TNF receptor superfamily of cellular and viral proteins. Activation, costimulation and death. Cell, 76, 959-962.
45. STAMENKOVIC I., CLARK E. A. and SEED B. (1989): A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J., 8, 1403-1410.
46. STRAUSS S. E., COHEN J. I., TOSATO G. and MEIER J. (1993): Epstein-Barr virus infections. Biology, pathogenesis, and management. Annu. Intern. Med., 118, 45-58.
47. TARTAGLIA L. A., AYRES T. M., WONG G. H. and GOEDDEL D. V. (1993): A novel domain within the 55 kd TNF receptor signals cell death. Cell, 74, 845-853.
48. THOMAS W. D., SMITH M. J., SI Z. and HERSEY P. (1996): Expression of the co-stimulatory molecule CD40 on melanoma cells. Int. J. Cancer, 68, 795-801.
49. TONG A. W. and STONE M. J. (1996): CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity. Leuk. Lymphoma, 21, 1-8.
50. UMETSU D. T., ESSERMAN L., DONLON T. A., DEKRUYFF R. H. and LEVY R. (1990): Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. J. Immunol., 144, 2550-2557.
51. VYTH-DREESE F. A., BOOT H., DELLEMUN T. A., MAJOOR D. M., OOMEN L. C. J. M., LAMAN J. D., MEURS M. V., DE WEGER R. A. and JONG D. D. (1998): Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology, 94, 580-586.
52. WINGETT D. G., VESTAL R. E., FORCIER K., HADJOKAS N. and NIELSON C. P. (1998): CD40 is functionally expressed on human breast carcinomas. Variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res. Treat., 50, 27-36.
53. XIERRI L., BOUABDALLAH R., DEVILARD E., HASSOUN J., STOPPA A.-M. and BIRG F. (1998): Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation. Br. J. Cancer., 78, 225-232.